检测３０例正常对照、２５例良性肺疾病、５５例非小细胞肺癌（ＮＳＣＬＣ）和１５例小细胞肺癌（ＳＣＬＣ）患者血清神经元特异性烯醇酶（ＮＳＥ）和胃泌素及其在治疗前后的动态变化，结果显示，血清ＮＳＥ和胃泌素在４组间差异有极显著性（Ｐ＜０００１），ＮＳＥ均值分别为８２２、１０８４、１４６４和３２００μｇ／Ｌ，胃泌素均值分别为５９４７、８２００、２２１５３和３５６８６ｎｇ／Ｌ。以２０３μｇ／Ｌ（ＮＳＥ）和８１４ｎｇ／Ｌ（胃泌素）为正常参考值上限，ＮＳＥ阳性率分别是８０％（ＳＣＬＣ）和１４５４％（ＮＳＣＬＣ），胃泌素分别是８０％（ＳＣＬＣ）和６３６３％（ＮＳＣＬＣ）。肺癌治疗后血清ＮＳＥ和胃泌素在ＳＣＬＣ组均显著下降（Ｐ＜０００１），而ＮＳＣＬＣ组仅有胃泌素降低（Ｐ＜０００１）。因此，ＮＳＥ主要用于ＳＣＬＣ的诊断、组织学分型及疗效监测，而胃泌素可以用于各型肺癌，两者联合可以提高临床应用价值。 Detection of serum neuron specific enolase (NSE) and gastrin in 30 normal controls, 25 benign lung diseases, 55 non-small cell lung cancer (NSCLC) and 15 small cell lung cancer (SCLC) patients and their treatment Before and after the dynamic changes, the results showed that the serum NSE and gastrin were significantly different between the four groups (P <0  001), the average NSE was 8  22, 10  84, 14  64 and 32  00 g g /L, mean values ​​of gastrin were 59  47, 82  00, 221  53, and 356  86 ng/L, respectively. The upper limit of normal reference was 203μg/L (NSE) and 814ng/L (gastrin). The positive rate of NSE was 80% (SCLC) and 1454% (NSCLC) respectively. Gastrin was 80% (SCLC) and 6363% (NSCLC). After treatment of lung cancer, serum NSE and gastrin in SCLC group were significantly decreased (P <0  001), while NSCLC group only gastrin decreased (P <0  001). Therefore, NSE is mainly used for the diagnosis of SCLC, histological type and efficacy monitoring, and gastrin can be used for various types of lung cancer, and the combination of the two can improve the clinical application value.